Needham & Company
-
Cidara Therapeutics to Participate in Upcoming Investor Conferences
-
Needham & Company Reiterates Buy Rating, $6 Price Target on Cidara Therapeutics (CDTX)
-
Needham & Company Reiterates Buy Rating on Cidara Therapeutics (CDTX)
-
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of
-
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of
-
Cidara Therapeutics (CDTX) Prices 14.84M Share Offering at $1.55/sh
-
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
-
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
-
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
-
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
-
Cidara Therapeutics (CDTX) PT Lowered to $6 at Needham & Company
-
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
-
Cidara Therapeutics (CDTX): Expecting A Positive Rezafungin Phase 2 Outcome In 1Q - Needham
-
Needham and Company Reiterates Buy Rating and $10 PT on Cidara Therapeutics (CTDX) Following Investor Day; 'Shares Attractive Ahead of Ph2 CD-101'
-
Cidara Therapeutics (CDTX) PT Lowered to $10 at Needham & Company; Keeps 'Buy'
-
Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
-
Cidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
-
Needham & Company Starts Cidara Therapeutics (CDTX) at Buy
-
Cidara Therapeutics (CDTX) IPO Opens Flat
-
Cidara Therapeutics (CDTX) IPO Prices at $16, Top End of Range
-
Cidara Therapeutics Announces Pricing of Initial Public Offering

